kicked off on Tuesday, with Esperion Therapeutics Inc. (NASDAQ: ESPR) stock price up 1.47% from the previous day of trading, before settling in for the closing price of $2.04. ESPR’s price has ranged from $0.70 to $3.40 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 7.64% over the last five years. Meanwhile, its annual earnings per share averaged 87.85%. With a float of $194.16 million, this company’s outstanding shares have now reached $196.22 million.
The firm has a total of 240 workers. Let’s measure their productivity. In terms of profitability, gross margin is 81.81%, operating margin of 1.78%, and the pretax margin is -35.46%.
Esperion Therapeutics Inc. (ESPR) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Esperion Therapeutics Inc. is 1.05%, while institutional ownership is 72.44%. The most recent insider transaction that took place on Sep 17 ’24, was worth 26,132. In this transaction President and CEO of this company sold 14,550 shares at a rate of $1.80, taking the stock ownership to the 752,266 shares. Before that another transaction happened on Sep 17 ’24, when Company’s Chief Commercial Officer sold 2,608 for $1.78, making the entire transaction worth $4,650. This insider now owns 162,659 shares in total.
Esperion Therapeutics Inc. (ESPR) Recent Fiscal highlights
In its latest quarterly report, released on 6/30/2024, the company reported earnings of -0.37 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.05 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 87.85% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.90% during the next five years compared to 23.09% growth over the previous five years of trading.
Esperion Therapeutics Inc. (NASDAQ: ESPR) Trading Performance Indicators
Here are Esperion Therapeutics Inc.’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.49. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.88, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach 0.18 in one year’s time.
Technical Analysis of Esperion Therapeutics Inc. (ESPR)
Analysing the last 5-days average volume posted by the [Esperion Therapeutics Inc., ESPR], we can find that recorded value of 4.51 million was lower than the volume posted last year of 6.45 million. As of the previous 9 days, the stock’s Stochastic %D was 84.71%. Additionally, its Average True Range was 0.14.
During the past 100 days, Esperion Therapeutics Inc.’s (ESPR) raw stochastic average was set at 31.82%, which indicates a significant decrease from 80.37% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 80.67% in the past 14 days, which was higher than the 76.56% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.84, while its 200-day Moving Average is $2.27. Now, the first resistance to watch is $2.13. This is followed by the second major resistance level at $2.19. The third major resistance level sits at $2.24. If the price goes on to break the first support level at $2.01, it is likely to go to the next support level at $1.96. Now, if the price goes above the second support level, the third support stands at $1.90.
Esperion Therapeutics Inc. (NASDAQ: ESPR) Key Stats
With a market capitalization of 406.18 million, the company has a total of 189,460K Shares Outstanding. Currently, annual sales are 116,330 K while annual income is -209,250 K. The company’s previous quarter sales were 73,830 K while its latest quarter income was -61,930 K.
